Which has stronger earnings and valuation, XNCR or CGON?

Xencor has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 16.46 -$91.92M -$2.17 N/A CG Oncology $4.04M 1,751.08 -$160.99M -$2.69 N/A

Is XNCR or CGON more profitable?

Xencor has a net margin of -155.59% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -155.59% -28.66% -20.38% CG Oncology -3,602.68% -25.20% -23.98%

Does the media refer more to XNCR or CGON?

In the previous week, CG Oncology had 7 more articles in the media than Xencor. MarketBeat recorded 9 mentions for CG Oncology and 2 mentions for Xencor. Xencor's average media sentiment score of 1.04 beat CG Oncology's score of 0.74 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XNCR or MIRM?

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Xencor. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 2 mentions for Xencor. Xencor's average media sentiment score of 1.04 beat Mirum Pharmaceuticals' score of 0.89 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRRK or XNCR more profitable?

Scholar Rock has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Xencor -155.59% -28.66% -20.38%

Does the media prefer SRRK or XNCR?

In the previous week, Scholar Rock had 7 more articles in the media than Xencor. MarketBeat recorded 9 mentions for Scholar Rock and 2 mentions for Xencor. Xencor's average media sentiment score of 1.04 beat Scholar Rock's score of 0.44 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COGT or XNCR?

In the previous week, Cogent Biosciences had 17 more articles in the media than Xencor. MarketBeat recorded 19 mentions for Cogent Biosciences and 2 mentions for Xencor. Xencor's average media sentiment score of 1.04 beat Cogent Biosciences' score of 0.69 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, XNCR or ERAS?

Xencor has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 16.46 -$91.92M -$2.17 N/A Erasca N/A N/A -$124.55M -$0.95 N/A

Is XNCR or ERAS more profitable?

Erasca has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -155.59% -28.66% -20.38% Erasca N/A -38.43% -32.05%

Does the media refer more to XNCR or ERAS?

In the previous week, Erasca had 2 more articles in the media than Xencor. MarketBeat recorded 4 mentions for Erasca and 2 mentions for Xencor. Xencor's average media sentiment score of 1.04 beat Erasca's score of 0.50 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xencor (XNCR) Competitors

$27.80 +0.80 (+2.96%)

As of 08/21/2026 04:00 PM Eastern

Compare

XNCR vs. CGON, MIRM, SRRK, COGT, and ERAS

Should you buy Xencor stock or one of its competitors? Xencor's main competitors and comparable companies include CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), Scholar Rock (SRRK), Cogent Biosciences (COGT), and Erasca (ERAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xencor compare to CG Oncology?

Xencor (NASDAQ:XNCR) and CG Oncology (NASDAQ:CGON) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Xencor has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	16.46	-$91.92M	-$2.17	N/A
CG Oncology	$4.04M	1,751.08	-$160.99M	-$2.69	N/A

Xencor currently has a consensus target price of $24.86, indicating a potential downside of 10.59%. CG Oncology has a consensus target price of $83.18, indicating a potential upside of 4.22%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts clearly believe CG Oncology is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, CG Oncology had 7 more articles in the media than Xencor. MarketBeat recorded 9 mentions for CG Oncology and 2 mentions for Xencor. Xencor's average media sentiment score of 1.04 beat CG Oncology's score of 0.74 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

26.6% of CG Oncology shares are owned by institutional investors. 5.1% of Xencor shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Xencor has a net margin of -155.59% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Summary

Xencor beats CG Oncology on 9 of the 16 factors compared between the two stocks.

How does Xencor compare to Mirum Pharmaceuticals?

Xencor (NASDAQ:XNCR) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Xencor currently has a consensus price target of $24.86, suggesting a potential downside of 10.59%. Mirum Pharmaceuticals has a consensus price target of $137.33, suggesting a potential upside of 42.60%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	16.46	-$91.92M	-$2.17	N/A
Mirum Pharmaceuticals	$521.31M	12.00	-$23.36M	-$14.55	N/A

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Xencor. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 2 mentions for Xencor. Xencor's average media sentiment score of 1.04 beat Mirum Pharmaceuticals' score of 0.89 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Mirum Pharmaceuticals has a net margin of -139.18% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Summary

Mirum Pharmaceuticals beats Xencor on 10 of the 15 factors compared between the two stocks.

How does Xencor compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Xencor (NASDAQ:XNCR) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Scholar Rock has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Xencor has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Scholar Rock has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Xencor	-155.59%	-28.66%	-20.38%

Xencor has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Xencor	$125.58M	16.46	-$91.92M	-$2.17	N/A

Scholar Rock presently has a consensus price target of $58.77, suggesting a potential upside of 4.02%. Xencor has a consensus price target of $24.86, suggesting a potential downside of 10.59%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Comparatively, 5.1% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Scholar Rock had 7 more articles in the media than Xencor. MarketBeat recorded 9 mentions for Scholar Rock and 2 mentions for Xencor. Xencor's average media sentiment score of 1.04 beat Scholar Rock's score of 0.44 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Scholar Rock and Xencor tied by winning 8 of the 16 factors compared between the two stocks.

How does Xencor compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Xencor (NASDAQ:XNCR) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Cogent Biosciences has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Xencor	-155.59%	-28.66%	-20.38%

Xencor has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Xencor	$125.58M	16.46	-$91.92M	-$2.17	N/A

Cogent Biosciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Xencor has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Cogent Biosciences currently has a consensus target price of $49.40, suggesting a potential upside of 34.49%. Xencor has a consensus target price of $24.86, suggesting a potential downside of 10.59%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cogent Biosciences is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Cogent Biosciences had 17 more articles in the media than Xencor. MarketBeat recorded 19 mentions for Cogent Biosciences and 2 mentions for Xencor. Xencor's average media sentiment score of 1.04 beat Cogent Biosciences' score of 0.69 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cogent Biosciences and Xencor tied by winning 7 of the 14 factors compared between the two stocks.

How does Xencor compare to Erasca?

Xencor (NASDAQ:XNCR) and Erasca (NASDAQ:ERAS) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Xencor has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Erasca has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

In the previous week, Erasca had 2 more articles in the media than Xencor. MarketBeat recorded 4 mentions for Erasca and 2 mentions for Xencor. Xencor's average media sentiment score of 1.04 beat Erasca's score of 0.50 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Erasca shares are held by institutional investors. 5.1% of Xencor shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Xencor has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	16.46	-$91.92M	-$2.17	N/A
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

Erasca has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
Erasca	N/A	-38.43%	-32.05%

Xencor currently has a consensus price target of $24.86, suggesting a potential downside of 10.59%. Erasca has a consensus price target of $22.09, suggesting a potential upside of 25.30%. Given Erasca's stronger consensus rating and higher probable upside, analysts plainly believe Erasca is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Erasca beats Xencor on 8 of the 15 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XNCR vs. The Competition

Export

Metric	Xencor	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.07B	$4.01B	$7.37B	$12.83B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-12.81	11.62	272.33	24.21
Price / Sales	16.46	1,341.06	625.25	96.46
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	3.12	17.38	11.25	6.42
Net Income	-$91.92M	-$22.72M	$3.47B	$348.89M
7 Day Performance	19.11%	3.29%	2.09%	0.08%
1 Month Performance	42.35%	8.23%	6.64%	3.88%
1 Year Performance	230.56%	55.05%	25.02%	16.98%

Xencor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XNCR Xencor	1.1629 of 5 stars	$27.80 +3.0%	$24.86 -10.6%	+230.6%	$2.07B	$125.58M	N/A	280	Positive News
CGON CG Oncology	2.1786 of 5 stars	$76.06 -1.4%	$83.18 +9.4%	+196.5%	$6.72B	$6.23M	N/A	61
MIRM Mirum Pharmaceuticals	3.5504 of 5 stars	$101.06 +1.2%	$137.33 +35.9%	+34.7%	$6.55B	$618.07M	N/A	140	Insider Trade
SRRK Scholar Rock	1.6469 of 5 stars	$53.47 +2.7%	$57.71 +7.9%	+59.2%	$6.49B	N/A	N/A	140	News Coverage Analyst Forecast
COGT Cogent Biosciences	2.4857 of 5 stars	$37.27 -1.6%	$49.40 +32.5%	+203.1%	$6.46B	N/A	N/A	80	Trending News Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XNCR) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xencor (XNCR) Competitors